TMEM92 and neoplasm: TMEM92 knockout reduced the cisplatin IC<sub>50</sub> by 44.0% in MDA-MB-231 cells and 42.9% in BT-549 cells, and TMEM92 depletion enhanced cisplatin-induced tumor growth inhibition by approximately 70.6% compared with cisplatin alone.<h4>Conclusions</h4>This study identifies a novel TMEM92DDX3XTTC3 axis that regulates DDX3X protein stability and drives TNBC progression and chemoresistance, revealing a potential prognostic and therapeutic vulnerability in TNBC.